Pharma & Life Sciences: R&D Acceleration with Cloud & AI

For a decade, drug R&D productivity barely moved while the cost of getting a single medicine to market climbed past $2 billion, and in some cases past $6 billion once you count the cost of failure and the cost of capital. Every major research house covering the industry has published a version of the same finding in the last two years: the science is ready, the models are ready, but most organizations are not capturing the value at scale.

This piece pulls together the sharpest findings from that research, adds the technical detail from AWS’s own Life Sciences guidance, and lays it out as something closer to a working playbook: what the opportunity actually is, what a modern R&D technology stack looks like, which use cases to start with, how to sequence the rollout, and where teams typically get stuck. We’ve added our own take at each stage, based on what we see in client engagements.

The size of the prize: Life Sciences in numbers

Mckinsey estimates that a top 10 biopharma company, with $65-75 billion in revenue, could capture $5-7 billion in peak value over five years by scaling AI across the business. Nearly 90% of that value sits in three places: R&D, manufacturing and supply chain, and commercial. R&D alone accounts for 30-45% of it, more than any other function, because AI touches both sides of the ledger there: it cuts the cost of failed programs and it can pull forward the revenue that comes from reaching the market sooner.

AWS puts a number on that speed. If companies use intelligent technologies at scale and rebuild workflows around them, they can bring a new medicine to market four years faster and earn an extra $2 billion per successful drug. Even a 1% improvement in clinical success rates is worth hundreds of millions in additional revenue. Latest analysis of AI-discovered molecules found a Phase 1 success rate of 80-90%, well above the historical industry average of 40-65%, though the sample size is still small enough that this needs watching rather than betting the portfolio on.

Value doesn’t land evenly across time, either. Our latest five-year value accretion modeling shows that enabling functions like IT, HR, and finance see savings fastest, while R&D and supply chain take longer to reach peak value because of long capital cycles. Within a single initiative, cost reductions typically show up in one to two quarters, while revenue gains take three to four quarters longer to materialize.

Why the value isn’t showing up yet: Dedicatted take on AI Acceleration

Recent analysis is the most direct about the root cause: most pharma companies run on patchwork infrastructure, decades of disconnected systems and workarounds layered on top of each other. This creates three specific failures. First, AI can’t reason reliably without semantic consistency; a system has no way of knowing that “PD marker” in discovery and “biomarker” in translational research mean the same thing unless someone tells it. Second, feedback loops break down, so what one program learns rarely reaches another. Third, scientists end up spending their time manually reconciling data between tools instead of doing science.

The pattern will sound familiar to anyone who has sat in a discovery or clinical ops meeting: a molecule generation tool produces strong candidates, but a chemist has to export the structures, reformat them, load them into a separate ADME tool, then copy results into a spreadsheet to cross-reference against synthetic accessibility scores, while historical data on why a similar scaffold failed three years ago sits in a slide deck that only one senior scientist remembers exists. Adding more point-solution AI tools on top of this doesn’t fix it. It adds another system to reconcile. Our answer is architecture-first, built on five pillars:

1. Platform-centric architecture – a shared, semantically consistent model of the R&D domain (schema, taxonomy, ontology, workflow logic), not a pile of vendor tools.
2. Data enablement backbone – breaking down data silos with data lakes, knowledge graphs, automated ingestion, and active data quality management.
3. AI-native workflows and talent – redesigning work so AI sits inside the decision path, not bolted on the side, paired with a genuinely hybrid workforce.
4. Governance, risk, compliance and security – making AI decisions auditable and building trust as a system property, not an afterthought.
5. Programmatic value capture – treating this as a portfolio of funded initiatives with real KPIs, not a collection of proofs of concept.

Organizations that commit to this for 12-24 months before expecting acceleration see 2-3x better AI adoption and model performance than those who layer AI onto the fragmentation they already have.

The reference architecture: what a modern R&D data and AI stack actually looks like

This is the technical layer most strategy reports skip, and it’s where projects actually succeed or stall. AWS’s Well-Architected Life Sciences Lens frames R&D workloads across drug discovery, bioinformatics, genomics, and connected labs, each with its own data volume, compute, and compliance profile. Below is how that maps to a practical stack.

Data layer: ingestion, storage, and governance

• Object storage as the foundation. Raw instrument output, sequencing files, imaging data, and lab notebook exports land in tiered object storage (hot for active analysis, cold/archive for long-term retention), because genomics data alone runs 100-200 GB per patient and organizations working across tens of thousands of patients cannot default to “keep everything hot.”
• A catalog and lakehouse layer on top, so structured trial data, unstructured lab notes, and omics data can be queried together instead of living in separate silos. This is where the “semantic stability” problem gets solved: a shared data catalog with consistent entity definitions (the same “PD marker” means the same thing in discovery and translational science) lets AI reason across the pipeline instead of within one tool at a time.
• Purpose-built genomics and omics tooling. Managed bioinformatics services exist specifically to run standard workflows (variant calling, alignment, annotation) at scale without every team building its own pipeline infrastructure from scratch, which is the direct answer to the “bioinformaticians spend too much time on infrastructure, not science” problem AWS’s own use case guidance calls out.
• FAIR by design. Findable, Accessible, Interoperable, Reusable data principles need to be enforced through metadata standards and access policies, not left as an aspiration in a data strategy slide.

Compute layer: matching workload to infrastructure

• High-performance computing (HPC) for molecular simulation and structure prediction, provisioned on demand rather than sized for peak load year-round.
• GPU-backed environments for generative chemistry and protein design models, separate from the general-purpose compute used for clinical data processing, since these workloads have very different cost and performance profiles.
• Managed ML environments for training, fine-tuning, and hosting models, rather than scientists standing up their own inference infrastructure ad hoc, which is one of the fastest ways to end up with the “shadow IT” version of the fragmentation problem we described before.

AI/ML and GenAI layer

• A model layer that supports both foundation models and specialized scientific models side by side. Literature summarization and document drafting are well served by general-purpose large language models; target identification and molecule generation need domain-specific models trained on biological and chemical data. Treating these as one undifferentiated “AI platform” is a common design mistake.
• Retrieval-augmented generation (RAG) over a governed knowledge base, so GenAI answers about targets, mechanisms, or prior program history are grounded in the company’s actual data rather than the model’s general training, which is also what keeps outputs auditable for regulators.
• An orchestration layer that chains these steps together (for example: literature mining, target scoring, and candidate shortlisting as one workflow) rather than leaving each capability as a standalone tool a scientist has to open separately.

Governance and compliance layer

• Identity, access, and encryption controls mapped to GxP context. Good Laboratory Practices govern the research and discovery stage, Good Clinical Practices govern trials, and Good Manufacturing Practices take over after approval. Access policies, audit logging, and data residency requirements differ across these three contexts, and a single undifferentiated security model tends to be either too loose for GMP data or too heavy-handed for early discovery work.
• Full audit trail and model lineage, covering what data trained or grounded a model, what version produced a given output, and who reviewed it, because this is exactly the evidence regulators are starting to ask for directly
• A responsible AI review step built into the workflow, not a separate committee that reviews things after the fact, to catch data bias and unintended consequences before a model output reaches a decision point.

The use case playbook, by R&D stage

Not every use case needs a five-year platform rebuild first. Here’s a working catalog organized by where value shows up across the R&D lifecycle, with the technical approach and expected value for each.

1.Bioinformatics and genomics at scale

Processing raw sequencing and omics data into usable insight, at a volume and cost that don’t scale linearly with headcount. Technical approach: Managed, reproducible bioinformatics pipelines (variant calling, alignment, annotation) running on elastic compute, with cost tiering between hot storage for active projects and archival storage for long-term retention, plus FAIR-compliant metadata so datasets stay usable across teams and over time.

Expected value: Removing infrastructure management from bioinformaticians’ day-to-day work lets them focus on the science rather than pipeline maintenance, and standardized, reusable workflows cut the time from raw data to interpretable insight. Our specialists have reworked this client’s drug discovery process on cloud infrastructure with the explicit goal of developing medicines faster, more cheaply, and with a higher chance of success, using machine learning across their research pipeline.

2.Connected labs

Bridges data silos between lab instruments, Laboratory Information Management Systems (LIMS), and Electronic Lab Notebooks (ELNs), so scientists see integrated, current data instead of hunting across systems. Technical approach: Instrument data capture piped from on-premises lab equipment into cloud analytics, governed under FAIR principles, with unstructured data (images, free-text notes) brought under the same governance model as structured results so AI tools can actually use it.

Expected value: Faster, more comprehensive access to research data across a lab network, and a foundation that makes AI-assisted analysis genuinely usable instead of blocked by missing or unreachable data. This technology has been used across roughly 4,000 research organizations and functions as a central data-sharing hub across decentralized labs, illustrating the direction most R&D organizations are heading even where they haven’t formally adopted a single platform yet.

We built a similar multi-agent platform for Cassen Testing Laboratories, an ISO 17025-accredited chemical and environmental lab in Toronto, whose reporting workflow was capped at ~50 markers per run, relied on manual regulatory checks, and took days per report. Using Amazon Bedrock with Nova models and AWS AgentCore, we deployed a supervisor agent coordinating specialized sub-agents for pattern detection, RAG-based retrieval, and traceable report assembly against a compound-to-pattern-to-source knowledge base. Throughput more than tripled to 150+ markers per run, new capabilities like VOC signature analysis became possible, and the same dataset now feeds both compliant technical reports and consumer-ready summaries.

3. Clinical trial design, recruitment, and monitoring

Uses digital twins, predictive models, and natural language processing to design smaller, faster, more representative trials, and to find and retain the right patients. Technical approach: Digital Twin Generator models trained on historical longitudinal patient data forecast disease progression for control-arm patients, reducing the number of control patients a trial actually needs. Separately, natural language processing over structured and unstructured patient records (EHRs, clinical notes, radiology reports) matches patients to trial protocols in real time.

Expected value: Digital twins can reduce the need for clinical trial enrollment by 25-50%, cutting both time and cost. In a retrospective analysis of three pivotal Phase III trials in mild-to-moderate Alzheimer’s disease, digital twins of trial participants enabled control arm size reductions of up to 33%, or a 13% boost in statistical power at the same sample size. Precision recruitment platforms let sites recruit patients three times faster than average, finding 25% more eligible patients while spending half the time searching. AI’s precision research platform matches patients and sites to trial protocols using natural language processing over clinical notes and radiology reports within a HIPAA-compliant environment.

4.Regulatory and quality documentation

Uses GenAI to draft, tag, and retrieve the enormous volume of documentation required for regulatory submissions and quality management. Technical approach: Semantic (meaning-based, not just keyword) search over a company’s own historical protocols, site contracting agreements, and clinical report forms, paired with GenAI drafting assistance for first drafts of clinical study reports and standard operating procedures, always with a human review step before anything is finalized.

Expected value: Faster identification of relevant materials during submission assembly, faster first-draft turnaround on recurring document types, and fewer costly misclassifications in quality event management, since undetected quality issues can carry significant regulatory penalties. We designed platform specifically to help biopharma clients speed up research and bring drugs to market faster using this kind of document- and knowledge-layer automation, governed by an internal responsible-AI framework.

Where we’d recommend starting

Pulling this together into a short list:

1. Run a structured architecture and data readiness assessment first. A Well-Architected style review against your research, clinical, and manufacturing data environments will tell you more about where you actually stand than any AI vendor demo.
2. Pick one no-regret use case, that touches data you already have in reasonably good shape, most often clinical trial recruitment or regulatory document drafting, and scope a pilot with a defined success metric before you build anything.
3. Build the data and governance foundation in parallel, not after the pilot succeeds. This is the work that determines whether use case number two is fast or painful.
4. Fund reskilling in the same budget cycle as the platform. The tools don’t create value on their own.
5. Bake in the audit trail and model validation evidence from day one, so your first regulatory submission that touches an AI-assisted output isn’t also your first attempt at documenting how that AI was validated.

None of this is a quick fix, and none of the research pretends otherwise. But the organizations already ahead on relative cycle times and technical success rates have also seen the largest growth in enterprise value over the same period, according to Accenture’s index. The two are connected.

If you’re evaluating where to start, whether that’s a Well-Architected review of your existing research data environment, a scoped GenAI pilot in clinical operations, a connected lab integration project, or a genomics pipeline modernization, that’s exactly the kind of conversation our team works through with clients regularly. As an AWS Premier Tier Services Partner and top 2% global AWS partner with GenAI Competency and MSP designation, we combine deep cloud expertise with hands-on engineering we are happy to compare notes on where your organization sits against this research.

Our teams bring the experience, AWS data and analytics expertise, and research initiatives to help you plan and execute your data-driven strategy. Get in touch with our team at Dedicatted to talk through where your environment stands today.